T Abruzzo1,2,3,4,5, K Abraham3, K B Karani3, J I Geller6, S Vadivelu7, J M Racadio8, B Zhang9,9, Z M Correa10,11,12. 1. From the Departments of Radiology (T.A., J.M.R.) tabruzzo@phoenixchildrens.com. 2. Departments of Neurosurgery (T.A.). 3. Radiology (KA., K.B.K., T.A.). 4. Department of Neurosciences (T.A.), Barrow Neurological Institute at Phoenix Children's Hospital, Phoenix, Arizona. 5. Departments of Radiology and Child Health (T.A.), University of Arizona College of Medicine, Phoenix, Arizona. 6. Oncology (J.I.G.), Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio. 7. Neurosurgery (S.V.). 8. From the Departments of Radiology (T.A., J.M.R.). 9. Epidemiology and Biostatistics (B.Z.). 10. Ophthalmology (Z.M.C.). 11. Ophthalmology (Z.M.C.), University of Cincinnati Medical Center, Cincinnati, Ohio. 12. Department of Ophthalmology (Z.M.C.), Wilmer Eye Institute, Johns Hopkins University Medical Center, Baltimore, Maryland.
Abstract
BACKGROUND AND PURPOSE: Selective ophthalmic artery infusion chemotherapy has improved ocular outcomes in children with retinoblastoma. Our aim was to correlate quantitative tumor reduction and dichotomous therapeutic response with technical and adjunctive factors during selective ophthalmic artery infusion chemotherapy for retinoblastoma. An understanding of such factors may improve therapeutic efficacy. MATERIALS AND METHODS: All patients with retinoblastoma treated by selective ophthalmic artery infusion chemotherapy at a single center during a 9-year period were reviewed. Only first-cycle treatments for previously untreated eyes were studied. Adjunctive factors (intra-arterial verapamil, intranasal oxymetazoline external carotid balloon occlusion) and technical factors (chemotherapy infusion time, fluoroscopy time) were documented by medical record review. Quantitative tumor reduction was determined by blinded comparison of retinal imaging acquired during examination under anesthesia before and 3-4 weeks after treatment. The dichotomous therapeutic response was classified according to quantitative tumor reduction as satisfactory (≥ 50%) or poor (<50%). RESULTS: Twenty-one eyes met the inclusion criteria. Patients ranged from 2 to 59 months of age. Adjuncts included intra-arterial verapamil in 15, intranasal oxymetazoline in 14, and external carotid balloon occlusion in 14. Quantitative tumor reduction ranged from 15% to 95%. Six showed poor dichotomous therapeutic response. A satisfactory dichotomous therapeutic response was correlated with intra-arterial verapamil (P = .03) in the aggregate cohort and in a subgroup undergoing treatment with single-agent melphalan at a dose of <5 mg (P = .02). In the latter, higher average quantitative tumor reduction correlated with intra-arterial verapamil (P < .01). CONCLUSIONS: Intra-arterial verapamil during selective ophthalmic artery infusion chemotherapy is correlated with an improved therapeutic response, particularly when treating with lower doses of single-agent melphalan.
BACKGROUND AND PURPOSE: Selective ophthalmic artery infusion chemotherapy has improved ocular outcomes in children with retinoblastoma. Our aim was to correlate quantitative tumor reduction and dichotomous therapeutic response with technical and adjunctive factors during selective ophthalmic artery infusion chemotherapy for retinoblastoma. An understanding of such factors may improve therapeutic efficacy. MATERIALS AND METHODS: All patients with retinoblastoma treated by selective ophthalmic artery infusion chemotherapy at a single center during a 9-year period were reviewed. Only first-cycle treatments for previously untreated eyes were studied. Adjunctive factors (intra-arterial verapamil, intranasal oxymetazoline external carotid balloon occlusion) and technical factors (chemotherapy infusion time, fluoroscopy time) were documented by medical record review. Quantitative tumor reduction was determined by blinded comparison of retinal imaging acquired during examination under anesthesia before and 3-4 weeks after treatment. The dichotomous therapeutic response was classified according to quantitative tumor reduction as satisfactory (≥ 50%) or poor (<50%). RESULTS: Twenty-one eyes met the inclusion criteria. Patients ranged from 2 to 59 months of age. Adjuncts included intra-arterial verapamil in 15, intranasal oxymetazoline in 14, and external carotid balloon occlusion in 14. Quantitative tumor reduction ranged from 15% to 95%. Six showed poor dichotomous therapeutic response. A satisfactory dichotomous therapeutic response was correlated with intra-arterial verapamil (P = .03) in the aggregate cohort and in a subgroup undergoing treatment with single-agent melphalan at a dose of <5 mg (P = .02). In the latter, higher average quantitative tumor reduction correlated with intra-arterial verapamil (P < .01). CONCLUSIONS: Intra-arterial verapamil during selective ophthalmic artery infusion chemotherapy is correlated with an improved therapeutic response, particularly when treating with lower doses of single-agent melphalan.
Authors: João Pessoa Souza Filho; Zelia Maria S Correa; Alexandre N Odashiro; Anamaria Baptista Coutinho; Maria Cristina Martins; Clélia Maria Erwenne; Miguel N Burnier Journal: Invest Ophthalmol Vis Sci Date: 2005-10 Impact factor: 4.799
Authors: H G Raaijmakers; M A Izquierdo; H M Lokhorst; C de Leeuw; J A Belien; A C Bloem; A W Dekker; R J Scheper; P Sonneveld Journal: Blood Date: 1998-02-01 Impact factor: 22.113
Authors: Todd A Abruzzo; James I Geller; Dale A Kimbrough; Samantha Michaels; Zélia M Corrêa; Kevin Cornell; James J Augsburger Journal: J Neurointerv Surg Date: 2014-09-01 Impact factor: 5.836
Authors: David H Abramson; Anthony B Daniels; Brian P Marr; Jasmine H Francis; Scott E Brodie; Ira J Dunkel; Y Pierre Gobin Journal: PLoS One Date: 2016-01-12 Impact factor: 3.240